Transcatheter aortic valve implantation was associated with significant regression of left ventricular mass from 202.4 g to 183.6 g at 1 year (P=0.04), without changes in LV function or size.
Observational (n=80)
Does transcatheter aortic valve implantation improve left ventricular mass regression and volumes in patients undergoing the procedure?
Transcatheter aortic valve implantation is associated with significant regression of left ventricular hypertrophy at 1 year, though without significant changes in LV systolic or diastolic function.
Tasa de eventos absoluta: 183.6% vs 202.4%
valor p: p=0.04
Objective The impact of transcatheter aortic valve implantation (TAVI) on left ventricular (LV) mass regression is not well defined. We aimed to measure LV mass regression, changes in LV volumes and dimensions, as well as mitral valve function after TAVI. Methods Eighty patients who underwent TAVI between 2008 and 2010 were studied. Echocardiographic findings before procedure and at 6- and 12-month follow-up were analyzed. Results Aortic valve area increased from 0.71 (0.27) cm 2 before procedure to 1.89 (0.64) cm 2 at 12 months ( P < 0.001), which was associated with reduction in peak 80.79 (23) vs 16.9 (6.5) mm Hg, P < 0.001 and mean 47.65 (14.2) vs 8.77 (3.29) mm Hg, P < 0.001 gradients. At 1 year, there was a change in LV end-systolic volume 46.12 (36.6) to 48.96 (4.05) mL, P = 0.042 and LV mass 202.4 (92.2) to 183.6 (98.2) g, P = 0.04. Left ventricular mass index regressed from 130.7 (28.9) to 122.1 (28.9) g/m 2 ( P = 0.01). Maximum wall thickness decreased from 1.28 (0.18) to 1.25 (0.17) cm ( P < 0.001). There was no significant change in LV ejection fraction, LV end-systolic and end-diastolic diameters, as well as mitral valve regurgitation. Conclusions Transcatheter aortic valve implantation is associated with significant regression of LV hypertrophy at 1 year. However, this regression was not associated with changes in LV systolic and diastolic functions, size, or changes in mitral valve regurgitation.
Zakkar et al. (Thu,) conducted a observational in Patients undergoing TAVI (n=80). Transcatheter aortic valve implantation (TAVI) vs. Baseline was evaluated on Left ventricular mass (g) (p=0.04). Transcatheter aortic valve implantation was associated with significant regression of left ventricular mass from 202.4 g to 183.6 g at 1 year (P=0.04), without changes in LV function or size.